Xior reported solid operational FY25 results. We remain very supportive of the excellent organic trends: LFL rental growth of +5.4% over FY25, which is expected to reach a minimum of +4% over 2026-27F, still outperforming the broader real estate space. The 4% EPS growth guidance for 2026 and 2027 is strong and we think this is a realistic expectation. LTV is at 49.9% and this limits growth options. Over the next two years the group focus will be on rental growth, operational leverage and the exe...
Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed
On 11/12/25, Xior already gave a heads up on the FY26 expected EPRA EPS of €2.30 and 4% growth yoy. This morning, Xior also issued a FY27e EPRA EPS of €2.40. Xior has stabilised its business and enjoys better visibility. The reported EPRA EPS25 of €2.21 came in line with their guidance and our €2.22 expectation. Xior NRI rose 7.2%, while like-for-like growth remained high at 5.43%. LTV% also fell below 50% at 49.7%. Xior expects growth thanks to a mix of factors: new assets + lfl growth of >4%...
As 3Q25 showed only 1% organic growth, this did not translate into the anticipated pick-up in growth rates. We expect meagre organic growth to continue into FY26 as we foresee only 1.8%, with 1H26 likely being slower than 2H26. New management has been taking measures to reduce overhead costs. These cost savings are material, but will only come fully to fruit in FY27, also the year when we foresee a return to stronger organic growth. With consensus in our view still too optimistic on organic grow...
MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in...
Arcadis has completed its share buyback program as of 16 January 2026. Since the launch of the program on 1 October 2025, the company repurchased a total of 4,575,796 ordinary shares for €175m, at an average price of €38.24. The shares acquired represent ca. 5% of the company's issued share capital and will be cancelled. We maintain our Hold.
Arcadis completes share buyback program and reports final transactions PRESS RELEASEArcadis completes share buyback program and reports final transactions Amsterdam, 20 January 2026 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, announced its share buyback program to be completed on 16 January 2026. Since the start of the share buyback program on 1 October 2025, a total of 4,575,796 ordinary shares have been repurchased for a total consideration of €174,999,566 at an avera...
La stabilisation des taux d’intérêt et de l’inflation devrait créer un climat plus favorable à l’investissement et permettre aux sociétés immobilières de poursuivre la mise en œuvre de leur feuille de route tout en faisant preuve de prudence. Dans ce contexte, le commerce et la logistique nous semblent les mieux positionnés et nous privilégions CTP, Merlin Properties, Shurgard, URW, VGP comme les plus à même d’exécuter leur stratégie de croissance. Nous relevons notre opinion à Surperformance su...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.